title: Deterioration of the metabolic risk profile in women. Respective contributions of impaired glucose tolerance and visceral fat accumulation.
abstract: OBJECTIVE
  To determine whether the impaired glucose tolerance (IGT) state contributes to the deterioration of the metabolic profile in women after taking into account the contribution of visceral adipose tissue (AT) accumulation, as measured by computed tomography.
  
  
  METHODS
  We studied 203 women with normal glucose tolerance (NGT) and 46 women with IGT, defined as a glycemia between 7.8 and 11.1 mmol/l measured 2 h after a 75-g oral glucose load.
  
  
  RESULTS
  Women with IGT were characterized by a higher visceral AT accumulation and by higher concentrations of fasting plasma glucose, insulin, and C-peptide as well as by higher plasma concentrations of cholesterol, triglycerides, and apolipoprotein B (apoB) and by greater cholesterol-to-HDL-cholesterol ratio, reduced LDL peak particle size, lower HDL-cholesterol and HDL2-cholesterol concentrations, and higher blood pressure (P < 0.01) than women with NGT. When we matched 27 pairs of women for visceral AT and fat mass as well as for menopausal status, differences previously found in LDL-cholesterol, LDL peak particle size, HDL-cholesterol, and HDL2-cholesterol concentrations as well as in the cholesterol-to-HDL-cholesterol ratio and blood pressure were eliminated, whereas triglyceride concentrations remained significantly higher in women with IGT.
  
  
  CONCLUSIONS
  A high visceral AT accumulation is a major factor involved in the deterioration of many metabolic variables in women with IGT, with the notable exception of triglyceride concentrations, which remained significantly different between women with NGT and women with IGT after adjustment for visceral fat.
authors.affiliation: Lipid Research Center, CHUQ Research Center, Laval University, Ste-Foy, Québec, Canada.
authors.forename: A
authors.initials: A
authors.lastname: Pascot
authors.forename: J P
authors.initials: JP
authors.lastname: Després
authors.forename: I
authors.initials: I
authors.lastname: Lemieux
authors.forename: N
authors.initials: N
authors.lastname: Alméras
authors.forename: J
authors.initials: J
authors.lastname: Bergeron
authors.forename: A
authors.initials: A
authors.lastname: Nadeau
authors.forename: D
authors.initials: D
authors.lastname: Prud'homme
authors.forename: A
authors.initials: A
authors.lastname: Tremblay
authors.forename: S
authors.initials: S
authors.lastname: Lemieux
mesh_terms: D000273:Adipose Tissue / Q000033:anatomy & histology* / Q000000981:diagnostic imaging; D000328:Adult; D000368:Aged; D001053:Apolipoproteins / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure; D002096:C-Peptide / Q000097:blood; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D002784:Cholesterol / Q000097:blood; D005260:Female; D018149:Glucose Intolerance / Q000453:epidemiology* / Q000503:physiopathology*; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008875:Middle Aged; D011792:Quebec; D018570:Risk Assessment; D012307:Risk Factors; D014057:Tomography, X-Ray Computed; D014280:Triglycerides / Q000097:blood; D014781:Viscera
chemical_list: D001053:Apolipoproteins; D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D008074:Lipoproteins; D014280:Triglycerides; D002784:Cholesterol